|Articles|July 5, 2018
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
Author(s)Michelle Maskaly
New Jersey is still a top pick for companies when it comes to pharma.
Advertisement
Ki-Young Sohn, chairman and CEO of Enzychem Lifesciences, explains why the company selected New Jersey as the location for their U.S. offices.
He spoke to Pharm Exec during a company event in New York City.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer’s Proven Playbook: Buy, Partner, Scale, Spin-Off, Optimize
2
HHS and FDA Appoint Richard Pazdur as Director of The Center for Drug Evaluation and Research
3
Bristol Myers Squibb Expands its Strategic Collaboration with Sarah Cannon Research Institute
4
AstraZeneca Stock Becomes UK’s Biggest Stock
5
